Q1-FY25 · Q4 FY24
FY25 EBITDA margin improvement of ~200bps YoY
Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
met
heuristic_v1
FORTIS / Q1-FY26 / promises
Measure what management said.
Fortis Healthcare · A quarter-by-quarter view of forward statements and whether delivery is visible yet.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Management delivery ledger
Promises over time.
Q1-FY25 · Q4 FY24
Brownfield bed addition of ~700 beds in FY25
Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
met
heuristic_v1
Q1-FY25 · Q4 FY24
Agilus put option resolution by Q2 FY25
Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
met
heuristic_v1
Q1-FY26 · Q4 FY25
Hospital revenue growth of 14-15% in FY26
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q1-FY26 · Q4 FY25
Agilus double-digit revenue growth and 23% EBITDA margin in FY26
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q2-FY24 · Q1 FY24
Hospital EBITDA margin target of 18-20%
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q2-FY24 · Q1 FY24
ARPOB growth of 4-5% for FY24
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q2-FY25 · Q1 FY25
Hospital EBITDA margin target of 20%+ for FY25
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q2-FY25 · Q1 FY25
Manesar 350-bed facility to be operational in Q2 FY25
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q2-FY26 · Q1 FY26
Hospital EBITDA margin improvement of ~200 bps for FY26
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q2-FY26 · Q1 FY26
Diagnostics EBITDA margin of 22-23% for FY26
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q2-FY26 · Q1 FY26
Add ~900 beds in FY26, ~50% operationalized this year
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q3-FY24 · Q2 FY24
250 beds to be added in FY24
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q3-FY25 · Q2 FY25
Hospital EBITDA margin expansion of 200 bps for FY25
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q3-FY26 · Q2 FY26
Hospital EBITDA margin to exceed initial guidance of 20.5-22.5%
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q3-FY26 · Q2 FY26
ARPOB growth of 5-6% in H2 FY26
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q4-FY24 · Q3 FY24
Hospital EBITDA margin target of 20% by end of FY24
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q4-FY24 · Q3 FY24
Occupancy expected to trend toward 70% in coming quarters
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q4-FY25 · Q3 FY25
Hospital margin guidance of 20.5% for FY25
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q4-FY25 · Q3 FY25
Diagnostics margin guidance of 21-22% for FY25
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1
Q4-FY25 · Q3 FY25
Manesar greenfield to break even by Q1 FY26
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
missed
heuristic_v1